Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY27 Earnings Presentation
17 slides from Ngl Fine-chem's earnings presentation, August 2026
Slide 1: NGL Fine-Chem Limited Investor Presentation Q1FY27
NGL Fine-Chem Limited INVESTOR PRESENTATION Q1FY27
Slide 2: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 3: Inside
Inside Pg. No. Pg. No. This Presentation 04 10 Q1FY27 Over view, Highlights Key Strengths and Strategy Pg. No. 15 Historical Financial Performance
Slide 4: Q1FY27 Highlights
01 Q1FY27 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T
Slide 5: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “Q1FY27 sustained the demand momentum we Against a loss of ₹4.5 crore in Q4FY26, we recorded witnessed in Q4FY26, with volumes remaining a forex gain of ₹2.5 crore in Q1FY27, providing a robust across our product segme nts and measurable uplift t o reported e
Slide 6: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q1FY26 Q4FY26 Q1FY27 PARTICULARS Q1FY26 Q4FY26 Q1FY27 ANIMAL API 92% 95% 95% TOP 3 PRODUCTS 30% 29% 31% HUMAN API 4% 2% 3% TOP 5 PRODUCTS 42% 44% 48% INTERMEDIATES 3% 1% 1% TOP 10 PRODUCTS 63% 66% 68% FORMULATIONS
Slide 7: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q1FY26 Q4FY26 Q1FY27 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 104.19 149.23 139.16 -6.75% 33.57% OTHER INCOME 6.35 2.46 7.43 202.05% 16.91% TOTAL INCOME 110.54 151.69 146.59 -3.36% 32.61% TOTAL OPERATING EXPENSES 93.21 127.82 115.88 -9.35% 24.
Slide 8: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY25 FY26 SHAREHOLDERS FUND 282.43 329.23 NON CURRENT LIABILITIES 31.99 66.25 LONG TERM BORROWINGS 25.34 56.40 CURRENT LIABILITIES 118.97 150.01 SHORT TERM BORROWINGS 48.00 52.02 TOTAL EQUITY AND LIABILITIES 433.39 545.50 NON CURRENT ASSETS 198.01 26
Slide 9: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY25 FY26 CASH FLOW FROM OPERATING ACTIVITIES 32.36 43.32 CASH FLOW FROM INVESTING ACTIVITIES (69.68) (70.59) CASH FLOW FROM FINANCING ACTIVITIES 37.46 29.55 NET CASH FLOW 0.14 2.27 CASH AT THE BEGINNING OF YEAR 0.40 0.53 CASH AT THE END OF YEA
Slide 10: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 11: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human
Slide 12: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT API SEGMENT CONCENTRATION Strong controls of processes with 95% in-house manufacturing and (₹ IN CRORES) 13% CAGR (OF SALES FY26) backward integrated facilities leading to cost competitiveness FY26 466 CUSTOMER PRODUCT F
Slide 13: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 5 manufacturing facilities located at Tarapur & Navi 20,000 m 2 168 kl 253 kl AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 14: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech a TO INCREASE • Additional capacities of CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • Capacity expansion with su
Slide 15: Historical Financial Performance
03 Historical Financial Performance 16 ROBUST FINANCIAL PERFORMANCE
Slide 16: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY26 501 FY26 73 FY26 48 FY25 368 FY25 34 FY25 21 FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 0 100 200 300 400 500 600 0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 GROSS MARGIN
Slide 17: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Shivam Gharat Abhishek Mehra Thank You NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, Maha